Oncostatin M Protein (OSM) (AA 26-221)

Catalog No. ABIN2666535

Recombinant Oncostatin M protein expressed in Escherichia coli (E. coli).

Quick Overview for Oncostatin M Protein (OSM) (AA 26-221) (ABIN2666535)

Target: Oncostatin M (OSM)

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 26-221

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 0.5 - 2.5 ng/ml, corresponding to a specific activity of 0.4 - 2.0 x 106

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in <20 % ACN, 0.1 % TFA.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: Oncostatin M (OSM)

Alternative Name: Oncostatin M

Background: Human oncostatin M (OSM) was initially isolated from supernatant of U937 cells treated with PMA. It was identified by its property to inhibit the proliferation of A375 melanoma cells and other human tumor cells. Bioinformatic homology analysis reveals that OSM has a similar composition and structure to LIF, G-CSF, and IL-6. OSM and LIF are located on human chromosome 22, and additional evidence suggests that these genes were derived by duplication of a common ancestral gene. In fact, many of its biological functions are shared with LIF. OSM binds two types of OSM receptor (OSMR) complexes. The type I receptor complex is composed of gp130 (IL-6 signal transducer) and LIF receptor β (LIFRβ) subunits. The type II receptor is constituted by the gp130 receptor and the OSMR β-chain. OSM also shares the OSMRβ-chain with the IL-31 receptor complex. The OSMRβ subunit is expressed by fibroblast, endothelial, hepatic, lung, and hematopoietic cells. The proinflammatory properties of OSM have been reported in skin, adipose tissue, lung, heart, and liver tissues. OSM triggers acute phase protein synthesis in hepatocytes. OSM is a potent inhibitor of keratinocyte proliferation and decreases the expression of both early and late keratinocyte differentiation markers. OSM transcripts are elevated in skin from psoriasis and atopic dermatitis patients, as compared with healthy skin. OSM and its receptor complexes play a key role in cutaneous inflammatory responses. In addition, OSM expression is increased in colonic biopsies of patients with active inflammatory bowel disease.

Molecular Weight: The 196 amino acid recombinant protein has a predicted molecular mass of approximately 22.1 kDa. The DTT-reduced and non-reduced protein migrate at approximately 20 kDa and 22 kDa, respectively, by SDS-PAGE. The predicted N-terminal amino acid is Ala.

Pathways: JAK-STAT Signaling, Negative Regulation of Hormone Secretion